Changchun High & New Technology subsidiary gets GenSci141 ointment trial accepted

Changchun High & New Technology Industry Group Co., Ltd. announced that its subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for its GenSci141 ointment. The application is for the domestic production and drug registration of the ointment.

GenSci141 ointment, a dihydrotestosterone ointment developed by GeneScience, is classified as chemical drug categories 2.2 and 2.4. It is intended for the treatment of micropenis in children caused by conditions such as hypogonadotropic hypogonadism, 5α-reductase 2 deficiency, congenital adrenal hyperplasia due to androgen synthesis deficiency, and idiopathic causes.

The company stated that successful progression of the clinical trial application would broaden its business structure, optimize its product portfolio, enrich strategic product lines, and enhance its core competitiveness. However, due to the high-tech, high-risk, and high-value-added nature of pharmaceutical products, the drug development, clinical trials, and production process are lengthy, multi-stage, and subject to uncertainties. Investors are advised to exercise caution and be aware of investment risks.